The total value of the transaction could be nearly $24 billion, including debt and future payouts.
The purchase also includes a 35-day period where Walgreens can solicit additional proposals. But given the deal’s potential size and complexity, a competing bid likely wouldn’t be successful, Leerink Partners analysts said in a Thursday note.
Rumors of the Sycamore sale, which could end Walgreens’ nearly 100-year run as a public company, have been circulating for months.
The deal isn’t surprising, given that Walgreens’ core retail pharmacy business is in “drastic need of changes” that would be challenging to undertake on the public markets, according to a Thursday note by TD Cowen analysts Charles Rhyee and Lucas Romanski.
The company’s share price has plummeted over the past decade as Walgreens faces lower prescription reimbursements and heightened retail competition. In first quarter results released in January, Walgreens reported an operating loss of $245 million compared to a loss of $39 million in the prior-year period.
by Emily Olsen
Source: biopharmadive.com
Stryker has started a limited market release of its Mako RPS handheld robotic system for total knee procedures, the company said Monday. Mako RPS, short for robotic power system, is aimed at surgeons who are interested in robotic technology but want the familiarity of a manual power tool, the company said.
The European Life Sciences Coalition (ELSC), which launched today in association with Belgium-based private capital association Invest Europe, also counts the likes of Forbion, Omega Funds and Cooley among its members. These members represent a combined 24 billion euros ($28.6 billion) in life science assets.
Sanofi announced changes to its leadership following a meeting of its Board of Directors on February 11, 2026. The Board decided not to renew the director mandate of Paul Hudson, whose tenure as Chief Executive Officer will end on February 17, 2026.
